ReviewWorld journal of transplantation2016
Immunological aspects of liver cell transplantation.
Review in World journal of transplantation, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Toward Next-Gen Cell Therapy for Pediatric Patients: Neonatal Hepatocytes Tolerate Electroporation-Mediated Gene Editing and Engraft in the Liver.The CRISPR journal · 2026Article
- Kupffer cells abrogate homing and repopulation of allogeneic hepatic progenitors in injured liver site.Stem cell research & therapy · 2024Article
- Successful induction of human chemically induced liver progenitors with small molecules from damaged liver.Journal of gastroenterology · 2022Article
- Molecularly Tailored Interface for Long-Term Xenogeneic Cell Transplantation.Advanced functional materials · 2022Article
- Transplantation of SDF-1α-loaded liver extracellular matrix repopulated with autologous cells attenuated liver fibrosis in a rat model.EXCLI journal · 2022Article
- Article
- Hepatocyte organoids and cell transplantation: What the future holds.Experimental & molecular medicine · 2021Review
- Alloresponses of Mixed Lymphocyte Hepatocyte Culture to Immunosuppressive Drugs as an In-Vitro Model of Hepatocyte Transplantation.Annals of transplantation · 2019Article
- Silencing of HLA class I on primary human hepatocytes as a novel strategy for reduction in alloreactivity.Journal of cellular and molecular medicine · 2019Article
- 3D human liver tissue from pluripotent stem cells displays stable phenotype in vitro and supports compromised liver function in vivo.Archives of toxicology · 2018Article
- Hepatocyte transplantation: past efforts, current technology, and future expansion of therapeutic potential.The Journal of surgical research · 2018Review
- Hepatocyte-induced CD4Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society · 2018Article
- Human hepatocyte transplantation for liver disease: current status and future perspectives.Pediatric research · 2018Review
- Clinical Hepatocyte Transplantation: What Is Next?Current transplantation reports · 2017Article
- Emerging advancements in liver regeneration and organogenesis as tools for liver replacement.Current opinion in organ transplantation · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Within the field of regenerative medicine, the liver is of major interest for adoption of regenerative strategies due to its well-known and unique regenerative capacity. Whereas therapeutic strategies such as liver resection and orthotopic liver transplantation (OLT) can be considered standards of care for the treatment of a variety of liver diseases, the concept of liver cell transplantation (LCTx) still awaits clinical breakthrough. Success of LCTx is hampered by insufficient engraftment/long-term acceptance of cellular allografts mainly due to rejection of transplanted cells. This is in contrast to the results achieved for OLT where long-term graft survival is observed on a regular basis and, hence, the liver has been deemed an immune-privileged organ. Immune responses induced by isolated hepatocytes apparently differ considerably from those observed following transplantation of solid organs and, thus, LCTx requires refined immunological strategies to improve its clinical outcome. In addition, clinical usage of LCTx but also related basic research efforts are hindered by the limited availability of high quality liver cells, strongly emphasizing the need for alternative cell sources. This review focuses on the various immunological aspects of LCTx summarizing data available not only for hepatocyte transplantation but also for transplantation of non-parenchymal liver cells and liver stem cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.